TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Nxera Pharma
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg

Nxera Pharma received a manufacturing approval to add a second API manufacturing site in Asia for QUVIVIQ®, aiming to improve supply resilience and reduce manufacturing costs for its insomnia treatment across the Asia-Pacific region.

Insights
FLDDW   positive

Company is expanding its bitcoin services, creating innovative partnerships, and working to mainstream cryptocurrency adoption


SGIOY   neutral

Mentioned as a commercial partnership for distribution and sales of QUVIVIQ® in Japan with a sales forecast of JPY 2.5 billion